Supernus CEO Khattar sells $3m in shares

Supernus Pharmaceuticals (NASDAQ:SUPN), a pharmaceutical company with impressive gross profit margins of 88.5% and a market capitalization of $2.76 billion, reported that CEO Jack A. Khattar sold 59,900 shares of company stock on October 9, 2025, for approximately $3 million. The sale comes as the stock trades near its 52-week high of $51.78, having gained over 57% in the past six months. The sales were executed in two tranches, with 58,371 shares sold at prices ranging from $50.11 to $51.09, and 1,529 shares sold at prices between $51.14 and $51.76.

On the same day, Khattar exercised options to acquire 81,250 shares of Supernus stock at a price of $25.30, totaling $2,055,625. These options were part of an employee stock option plan.

Following these transactions, Khattar directly owns 1,206,578 shares of Supernus Pharmaceuticals. He also indirectly owns 1,005,600 shares through the KBT Trust.

In other recent news, Supernus Pharmaceuticals reported its second-quarter 2025 earnings, showcasing a mixed performance. The company exceeded revenue expectations with $165 million, compared to the consensus estimate of $154.3 million. However, earnings per share were $0.40, falling short of the anticipated $0.48. Stifel raised its price target for Supernus Pharmaceuticals to $43 from $38, acknowledging the strong quarterly performance driven by its Qelbree and Gocovri products. Piper Sandler also upgraded its rating for Supernus Pharmaceuticals from Neutral to Overweight, citing the potential of Onapgo, their infusion pump for Parkinson’s disease. Piper Sandler now estimates U.S. peak sales for Onapgo could surpass $300 million. Similarly, Cantor Fitzgerald increased its price target to $63, noting a faster-than-expected adoption rate of Onapgo. These developments reflect the growing confidence in Supernus Pharmaceuticals’ product lineup and market potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.